Lumen Bio
PrivateLast Round
Series C
Extension
Oct 8, 2025
Total Funding Raised
$56M
Company Overview
Lumen Bio operates in Healthcare & Life Sciences and is based in Seattle, Washington. Its latest recorded funding round was a Series C Extension round in October 2025.
Lumen Bioscience is a biotechnology company that develops orally delivered biologic drugs for highly prevalent diseases using a proprietary spirulina-based biomanufacturing platform.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Clinical Trials, Clean Manufacturing
Business Model
B2B
Customer Profile
Government Contracts, Services & Consulting
AI Layer
Application
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Lumen Bio Comparables
Compare Lumen Bio with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Vedanta Biosciences | 73% | |
| Seres Therapeutics Inc | 65% | |
| Rani Therapeutics | 62% |
For institutional investors. Book with your work email.
Lumen Bio Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series C Extension | Oct 8, 2025 | ||||
| Grant | Jan 4, 2023 | ||||
| Grant | Jan 4, 2023 | ||||
| Grant | Jan 27, 2021 | ||||
| Grant | Sep 24, 2020 | ||||
Series A | Dec 5, 2017 |
For institutional investors. Book with your work email.
Key People
Founding team and executive leadership
For institutional investors. Book with your work email.
Lumen Bio Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| CARB-X | Grant |
| Gates Foundation | Grant, Series C Extension |
| Bioeconomy Capital | Series A, Grant |
| WestRiver Group | Grant, Series C Extension |
| Columbia Pacific Advisors | Grant |
| Medical Technology Enterprise Consortium | Grant |
| Department of Energy | Grant |
For institutional investors. Book with your work email.
Market signals
Structured signals derived from secondary market and firmographic data.
- Mar 28, 2025
Monthly visitors grew 204% MoM.
- Oct 27, 2024
Monthly visitors grew 160% MoM, reaching 710.
For institutional investors. Book with your work email.
Lumen Bio Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.
Frequently Asked Questions
Common questions about Lumen Bio's valuation, stock price, and market status.
Is Lumen Bio a public or private company?
Lumen Bio is a private company.
What is the current stock price of Lumen Bio?
Lumen Bio is a private company, so its shares have no public market price. Caplight tracks Lumen Bio's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is Lumen Bio worth (valuation)?
Valuation information for Lumen Bio is not publicly available.
Can I buy Lumen Bio stock?
Lumen Bio shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was Lumen Bio's last funding round?
Lumen Bio's most recent funding round was Series C Extension on October 8, 2025.
Who are the main investors in Lumen Bio?
Key investors in Lumen Bio include Bioeconomy Capital, WestRiver Group, Avista Development.
Will Lumen Bio IPO soon?
No public IPO plans have been announced for Lumen Bio.
How can I track Lumen Bio secondary market activity?
Caplight tracks bids, offers, and trades in Lumen Bio's shares on secondary markets.